Sławomira Kyrcz-Krzemień

Sławomira Kyrcz-Krzemień

Auto-generated profile, based on publicly available information

Sławomira Kyrcz-Krzemień

Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Katowice, Poland

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2010 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
SGS Giebel
S Giebel
JDJ Dziaczkowska
J Dziaczkowska
TCT Czerw
T Czerw
JWJerzy Jan Wojnar
Jerzy Jan Wojnar
MKM Krawczyk-Kulis
M Krawczyk-Kulis
JHJ Holowiecki
J Holowiecki

16 October 2009 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Open access
PDF file
KMKatarzyna Mrówka-Kata
Katarzyna Mrówka-Kata
DKDariusz Kata
Dariusz Kata
SKSławomira Kyrcz-Krzemień
Sławomira Kyrcz-Krzemień
GHGrzegorz Helbig
Grzegorz Helbig
Kikuchi–Fujimoto disease (KFD), also known as histiocytic necrotizing lymphadenitis, is a benign and self-limiting disease typically characterized by the enlargement of regional lymph nodes and accompanied by fever. KFD affects predominantly young adult females of Asian origin and is rarely seen in European countries, where it may cause diagnostic difficulties. Kimura disease is a rare and benign chronic inflammatory soft tissue disorder of unknown origin, characterized by a triad of painless subcutaneous masses in the head or neck region accompanied by regional lymphadenopathy, blood and tissue eosinophilia, and markedly elevated serum immunoglobulin E levels. Although most cases of Kimura disease have originated in China, Japan or Southeast Asia, there have been sporadic case reports from Europe and America. Herein, we review in detail the clinical presentations, complications and current concepts in the pathogenesis, diagnosis and treatment of these diseases.

1 November 2016 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
GHGrzegorz Helbig
Grzegorz Helbig
JDJoanna Dziaczkowska-Suszek
Joanna Dziaczkowska-Suszek
TFTomasz Francuz
Tomasz Francuz
KTKarolina Torba
Karolina Torba
SKSławomira Kyrcz-Krzemień
Sławomira Kyrcz-Krzemień

14 May 2015 in Cytokine
Verified
Journal Article
Closed access
KBKatarzyna Bogunia-Kubik
Katarzyna Bogunia-Kubik
SMSylwia Mizia
Sylwia Mizia
MPMałgorzata Polak
Małgorzata Polak
AGAnna Gronkowska
Anna Gronkowska
JNJacek Nowak
Jacek Nowak
Andrzej LangeAndrzej Lange
Andrzej Lange

16 November 2004 in Blood
Verified
Journal Article
Open access
JHJerzy Holowiecki
Jerzy Holowiecki
SGSebastian Grosicki
Sebastian Grosicki
Ewa RobakEwa Robak
Ewa Robak
SKSlawomira Krzemien
Slawomira Krzemien
SGSebastian Giebel
Sebastian Giebel
ADAnna Dmoszynska
Anna Dmoszynska
The goal of the study was to evaluate long-term outcome of acute myeloid leukemia (AML) patients treated within the PALG 1999 DAC vs, DA Study. Between 1999–2002, 445 patients, aged 18–60 years, were randomized to the induction DAC-7: daunorubicin 60 mg/m2/d iv 1–3; cytarabine 200 mg/m2/d ci 1–7; cladribine 5 mg/m2 2h inf. iv d 1–5 or standard DA-7 regimen (the same regimen without cladribine). Patients achieving CR received two courses of subsequent intensive consolidation: 1) HAM (HD AraC, mitoxantrone) 2) HD AraC with or without cladribine in the DAC-7 or DA-7 arm, respectively. In case of PR after the first induction course the same regimen was repeated, NR patients received CLAG (2-CDA, HD-AraC, G-CSF), regardless the randomization arm. Post-consolidation therapy was in both arms comparable. As previously reported, a single course of DAC-7 induction resulted in 17% higher CR rate compared to the DA-7 treatment. The difference was particularly pronounced in a population of patients >40 years and for those with initial WBC >100x109/L. In the latter subgroup also the overall CR rate (achieved after >=1 induction course) was higher in the DAC-7 arm (71% vs. 43%). [Leukemia. 2004 May;18(5):989–97] In the present report we analyzed long-term outcome (median follow-up 3.2 years) in the whole study group and in pre-defined subgroups taking into account initial tumor burden, age, cytogenetics, FAB subtype, and preceding myelodysplasia. At five years the overall survival (OS) rate equaled 31% for DAC-7 and 25% for DA-7 arm (p=0.42) and leukemia free survivall (LFS) 32% vs. 29% (p=0.38), respectively. The subgroup analysis revealed higher probability of the OS in patients with initial WBC ≥100 G/l assigned to DAC-7 compared to DA-7 arm (39% vs. 11%, p=0.02). The LFS rate and the probability of relapse equaled 50% and 32% (p=NS) and 36% and 68% (p=0.0497), respectively. In patients aged >40 years, the therapy containing cladribine was associated with improved LFS (30% for DAC-7 vs. 20% for DA-7, p=0.01), and a tendency to improved OS (28% vs. 18%, p=0.09). In this subgroup DAC-7 therapy resulted in reduced relapse incidence (60% vs. 69%, p=0.04).We conclude that addition of cladribine to induction/consolidation therapy of AML may improve long-term outcome in higher age ranges patients and in those with high tumor burden. The improvement results mainly from reduced risk of relapse, and, in patients with high initial WBC, from higher CR rate.